135 results
Page 4 of 7
8-K
EX-99.2
dxi4ko6fs tq7oo
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.1
pl69z8en xo
4 Nov 19
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
7:07am
8-K
EX-99.1
ogj9mlj71 haamwk
6 Aug 19
Results of Operations and Financial Condition
7:13am
8-K
EX-99.1
4naj9j6bcas9
3 Jul 19
Karyopharm Announces FDA Approval of XPOVIOTM(selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
1:10pm
8-K
EX-99.1
d5ay88npvog 4qo
19 Jun 19
Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
4:05pm
8-K
EX-99.1
s5jczpk12semcms8q6w1
14 Jun 19
Other Events
7:33am
8-K
EX-99.1
nulto
9 May 19
Results of Operations and Financial Condition
7:10am
PRE 14A
r5kfhr zljegr709
2 Apr 19
Preliminary proxy
4:29pm
8-K
EX-99.1
3386ya1p2s13wfr8
28 Feb 19
Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
7:22am
8-K
EX-99.1
ugo5vrg cz
7 Jan 19
Regulation FD Disclosure
8:26am
8-K
EX-99.1
nlk1gy4 tmsr
3 Dec 18
Other Events
4:06pm
8-K
EX-99.2
cxodxtlo9crk
3 Dec 18
Other Events
4:06pm
8-K
EX-99.1
6im1hfzu
8 Nov 18
Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
7:08am